Bio News
GC Biopharma has entered into a partnership with French vaccine company Osivax to develop and commercialize a next-generation influenza vaccine. The companies will develop a combination vaccine that pairs GC Biopharma’s GC Flu with Osivax’s influenza A vaccine candidate OVX836. GC Biopharma secured exclusive rights for commercialization in South Korea and long-term supply rights for GC Flu.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
